Her research focuses on hereditary causes of breast cancer and effective strategies for breast cancer prevention and treatment. Dr Tung was involved in the studies that led to approval of the current breast cancer prevention medications. Much of her research focuses on women with BRCA1 and BRCA2 mutations, studying the genetic and environmental factors that influence cancer development as well as the biology and prognosis of the breast cancers they develop. Dr Tung also oversees many trials evaluating the optimal treatment for patients with hereditary breast cancer including a multicenter, national trial comparing cisplatin to standard chemotherapy in BRCA1/2 mutation carriers with newly diagnosed breast cancer. She is also leading studies evaluating novel therapies, such as PARP inhibitors, to treat hereditary breast cancer. She is a lead author for the OlympiAD trial, demonstrating the superiority of the PARP inhibitor olaparib to chemotherapy for BRCA mutation carriers with advanced breast cancer.